Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands.
Int J Biol Markers. 2009 Jul-Sep;24(3):130-41. doi: 10.1177/172460080902400302.
Novel diagnostic breast cancer markers have been extensively searched for in the proteome, using, among others, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Thus far, the majority of SELDI-TOF MS studies have investigated samples originating from biorepositories, which hampers biomarker discovery as they likely suffer from variable adherence to collection protocols.
We investigated breast cancer (n=75) and control (n=26) serum and tissue samples, collected prospectively by rigorous adherence to a strictly defined protocol. Sera were collected preoperatively and postoperatively, and serum and tissue samples were analyzed by SELDI-TOF MS using the IMAC30 Ni and Q10 pH 8 array.
Three serum peaks were significantly associated with breast cancer, while in tissue, 27 discriminative peaks were detected. Several peak clusters gradually increased or decreased in intensity from healthy to benign to cancer, or with increasing cancer stage. The constructed classification trees had a tenfold cross-validated performance of 67% to 87%. Two tissue peaks were identified as N-terminal albumin fragments. These are likely to have been generated by (breast) cancer-specific proteolytic activity in the tumor microenvironment.
These albumin fragment scan potentially provide insights into the pathophysiological mechanisms associated with, or underlying, breast cancer, and aid in improving breast cancer diagnosis.
利用表面增强激光解吸/电离飞行时间质谱(SELDI-TOF MS)等技术,在蛋白质组学中广泛搜索新型诊断乳腺癌标志物。迄今为止,大多数 SELDI-TOF MS 研究都集中在生物库来源的样本上,这阻碍了生物标志物的发现,因为它们可能无法严格遵守采集协议。
我们前瞻性地收集了严格遵循严格定义的方案的乳腺癌(n=75)和对照(n=26)血清和组织样本。术前和术后采集血清,并用 IMAC30 Ni 和 Q10 pH 8 阵列通过 SELDI-TOF MS 分析血清和组织样本。
三个血清峰与乳腺癌显著相关,而在组织中检测到 27 个有区别的峰。几个峰簇的强度逐渐从健康、良性、癌症或癌症分期增加或减少。构建的分类树的 10 倍交叉验证性能为 67%至 87%。两个组织峰被鉴定为 N 端白蛋白片段。这些片段可能是由肿瘤微环境中(乳腺癌)特异性的蛋白水解活性产生的。
这些白蛋白片段扫描可能提供有关与乳腺癌相关或潜在的病理生理机制的见解,并有助于改善乳腺癌的诊断。